Weight loss is the one goal where some peptides have strong human evidence, because the GLP-1 class includes approved medicines with large trials behind them. Others marketed for fat loss have far weaker support. Sorting them by evidence is the most useful thing this page can do.
Reviewed for accuracy · Last reviewed July 8, 2026The compounds below are the ones most discussed for weight loss. Each links to its full profile, where the dosing, side effects, and sources live. They are ordered roughly by how much human evidence sits behind them, not by a claim that any one works.
The gap between the top and bottom of this list is large. The GLP-1 class (tirzepatide, semaglutide) has approved labels and Phase 3 evidence, while AOD-9604 has human trials that did not demonstrate meaningful weight loss. Retatrutide sits in between: promising Phase 2 data but no approval.
For the approved GLP-1 peptides, most people sourcing vials independently rather than as a prescribed pen need to convert milligrams to insulin-syringe units, which the compound pages and calculators cover. Independently sourced material of any of these carries no guarantee of the testing a regulated product does.
This page is an independent educational reference and is not medical advice, and does not indicate any approval status for any use. Talk to a doctor before starting any compound.